title: Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
abstract: Medicinal chemistry strategies have contributed to the development, experimental study of and clinical trials assessment of the first type of protein kinase small molecule inhibitor to target the Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling pathway. The orally administered small molecule inhibitor, tofacitinib, is the first drug to target the JAK/STAT pathway for entry into the armamentarium of the medical therapy of rheumatoid arthritis. The introduction of tofacitinib into general rheumatologic practice coupled with increasing understanding that additional cellular signal transduction pathways including the mitogen-activated protein kinase and phosphatidylinositide-3-kinase/Akt/mammalian target of rapamycin pathways as well as spleen tyrosine kinase also contribute to immune-mediated inflammatory in rheumatoid arthritis makes it likely that further development of orally administered protein kinase small molecule inhibitors for rheumatoid arthritis will occur in the near future.
authors.affiliation: Charles J Malemud, David E Blumenthal, The Arthritis Research Laboratory, Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University, Cleveland, OH 44106-5076, United States.
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Malemud
authors.affiliation: Charles J Malemud, David E Blumenthal, The Arthritis Research Laboratory, Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University, Cleveland, OH 44106-5076, United States.
authors.forename: David E
authors.initials: DE
authors.lastname: Blumenthal
keywords: Clinical trials; Protein kinase; Rheumatoid arthritis; Signal transduction; Small molecule inhibitor